<DOC>
	<DOCNO>NCT00897130</DOCNO>
	<brief_summary>Azacitidine give dose 75 mg/sqm ( s.c ) daily 5 consecutive day every 28 day ( every month ) total 8 course low risk MDSs accord IPSS scoring system . In fact , several study produce high rate trilineage response , reduces risk progression acute myeloid leukemia ( AML ) high-risk MDS improve quality life ( QoL ) . The use 5-Aza earlier phase MDS could reduce proliferative advantage MDS clone favour regrowth normal hematopoiesis .</brief_summary>
	<brief_title>5-Azacitidine Low-risk Myelodysplastic Syndromes ( MDSs )</brief_title>
	<detailed_description>5-Azacitidine ( 5-AZA ) promise drug treatment MDSs . When administer dose 75mg/m2/day subcutaneously 7 day , every 28 day ( every month ) , 5-Aza produce high rate trilineage response , reduces risk progression AML high-risk MDS improve QoL . The use 5-Aza earlier phase MDS could reduce proliferative advantage MDS clone favour regrowth normal hematopoiesis . Other dos schedule could improve efficacy . Gene expression profile study MDS patient sensitive resistant 5-AZA lacking data come study could useful clarify mechanisms 5-azacitidine optimize therapy . Objectives study Primary : - To evaluate efficacy ( hematologic response ) toxicity 5-Aza five day monthly treatment schedule patient low-risk MDS ( IPSS 0-INT1 ) Secondary : - To evaluate QoL FACT-An questionnaire - To evaluate time progression MDS ; - To evaluate gene expression profile MDS patient sensitive resistant 5-AZA ; - To evaluate oncostatin M , interleukin-6 interleukin-11 level responder non responder . Azacitidine give dose 75mg/sqm subcutaneous daily 5 consecutive day every 28 day ( every month ) total 8 course . 5-Aza dosage adjust follow : Patients ' care medication - RBC transfuse maintain Hb level &gt; 90 g/L , whenever indicate . - Platelets transfuse platelet count &lt; 20 x 109/L , whenever indicate . - EPO allow trial time ( 8 months= 8 course 5-AZA therapy ) - Granulocyte granulocyte-monocyte colony stimulate factor ( G-CSF GM-CSF ) allow case severe neutropenia and/or systemic infection . - Antibiotics antifungal per o give prophylaxis neutrophil &lt; 0.5 x 109 /L . - Antibiotics give i.v . case fever ( &gt; 38°C &gt; 24 h ) whenever indicate . - Antifungals give i.v . case fever persist 5 day antibiotic i.v . whenever indicated . - Other experimental drug agent allow . - If another experimental drug agent administer , patient must discontinue treatment 5-AZA , go off-study . Definition Response The response treatment assess accord IWG 2006 criterion , report Cheson et al . ( 28 ) ( Appendix F ) Response criterion alter natural history MDS : - Complete remission ( CR ) Bone marrow : ≤5 % myeloblast normal maturation cell line Persistent dysplasia note Peripheral blood : Hgb ≥ 11g/dl , Platelets ≥ 100 x 109/l , Neutrophils ≥ 1.0 x 109/l , Blasts 0 % - Partial remission ( PR ) All CR criterion abnormal treatment except : Bone marrow blast decrease ≥50 % pretreatment still &gt; 5 % Cellularity morphology relevant - Marrow CR Bone marrow ≤ 5 % myeloblast decrease ≥ 50 % pretreatment Peripheral blood : HI response , note addition marrow CR - Stable disease Failure achieve least PR , evidence progression &gt; 8 week - Failure Death treatment disease progression characterize worsen cytopenia , increase percentage bone marrow blast , progression advance MDS FAB subtype pretreatment . - Relapse CR PR At least one following : - Return pretreatment bone marrow blast percentage - Decrement ≥ 50 % maximum remission/response level granulocytes platelet - Reduction Hgb concentration ≥ 1.5 g/dl transfusion dependence - Cytogenetic Response 1 . Complete Disappearance chromosomal abnormality without appearance new one 2 . Partial At least 50 % reduction chromosomal abnormality - Disease progression For patient Less 5 % blast : ≥50 % increase blast &gt; 5 % blast 5 % -10 % blast : ≥50 % increase &gt; 10 % blast 10 % -20 % blast : ≥ 50 % increase &gt; 20 % blast 20 % -30 % blast : ≥50 % increase &gt; 30 % blast Any follow At least 50 % decrement maximum remission/response granulocyte platelet Reduction Hgb ≥ 2g/dl Transfusion dependence Survival Endpoints : Overall : death cause Event free : failure death cause PFS : disease progression death form MDS DFS : time relapse Cause-specific death : death related MDS Response criterion hematologic improvement ( HI ) - Erythroid response ( HI-E ) ( pretreatment , &lt; 11 g/dl ) Hgb increase ≥1.5 g/dl Relevant reduction unit RBC transfusion absolute number least 4 RBC transfusions/8 week compare pretreatment transfusion number previous 8 week . Only RBC transfusion give Hgb ≤ 9.0 g/dl pretreatment count RBC transfusion response evaluation - Platelet response ( HI-P ) ( pretreatment , &lt; 100 x 109/l ) Absolute increase ≥ 30 x 109/l patient start &gt; 20 x 109/l platelet Increase &lt; 20 x 109/l &gt; 20 x 109/l least 100 % - Neutrophil response ( HI-N ) ( pretreatment , &lt; 1.0 x 109/l ) At least 100 % increase absolute increase &gt; 0.5 x 109/l - Progression relapse HI 1 . At least one following : 2 . At least 50 % decrement maximum response level granulocytes platelet 3 . Reduction Hgb ≥ 1.5 g/dl Transfusion dependence Quality Life ( QoL ) QoL assess FACT-An score treatment monthly study , end cycle treatment . The FACT-An questionnaire perform outpatient interview one train nurse The QoL battery , accord FACT-An questionnaire , consist item include physical , functional , emotional , social spiritual symptom Patient evaluation - Physical examination ( entry every month ) . - Peripheral blood count differential ( entry every two week ) . - Bone marrow biopsy ( entry ; end 4th course ; end study-8th course ) . - Bone marrow aspirate ( entry ; end 4th course ; end study-8th course ) . - Cytogenetics ( entry ; end 4th course ; end study -8th course ) . - Blood biochemistry profile ( entry every month ) . - HBV , HCV , HIV ( entry ) . - Gene Profile ( entry ; end 4th course ; end study-8th course ) . - Cytokines , Onc.M , IL6 , IL11 ( entry ; end 4th course ; end study-8th course ) . - FACT-an ( entry ; end course ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients lowrisk ( IPSS 0INT1 ) MDS accord WHO classification , present one following : Symptomatic anemia require RBC transfusion supportive therapy previously unresponsive EPO expect respond EPO Thrombocytopenia require platelet transfusion without mucocutaneous haemorrhagic syndrome Persistent ( &gt; 3 month ) absolute neutrophil count le 1,5 x 109/L , without infection , require myeloid growth factor therapy ≥ 18 year old . Life expectancy ≥ 3 month . ECOG performance Status Grade 02 . Serum bilirubin level ≤ 1.5 upper limit normal ( ULN ) Serum GOT GPT level ≤ 2x UNL . Creatinine level ≤ 1.5x UNL . Negative serum βhuman chorionic gonadotropin ( βHCG ) pregnancy test 24 hour prior begin therapy 5AZA , fertile woman . Written informed consent . Patients MDS accord WHO classification INT2 high IPSS risk . Life expectancy &lt; 3 month . ECOG performance Status Grade &gt; 2 . Serum bilirubin level &gt; 1.5 upper limit normal ( ULN ) . Serum GOT GPT level &gt; 2 x UNL . Creatinine level &gt; 1.5 x UNL . Pregnancy breast feed . Insulindependent diabetes uncontrolled non insulindependent diabetes . Severe cardiac pulmonary disease incompatible conduction protocol . Patient clear indication receive longterm anticoagulant therapy . Other active hematologic solid tumor . Severe CNS disease . Malignant hepatic tumor . Hypersensitivity mannitol azacitidine . No write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>low-risk ( IPSS 0-INT1 ) MDS accord WHO classification</keyword>
</DOC>